News / Taiwan / cnyes
Mabtech (4726) Reports 131% Surge in August Revenue
Health Technology · Biotechnology · cnyes · 2026-09-08
4726
Mabtech announced its August 2026 revenue reached NT$106 million, marking a 131.44% year-over-year increase and a 23.14% monthly growth.
What Happened
Revenue Performance: Mabtech (4726) reported a strong revenue figure of NT$106 million for August 2026. This represents a significant year-over-year growth of 131.44% and a monthly increase of 23.14%.
Cumulative Results: For the first eight months of 2026, the company's cumulative revenue reached NT$592 million. This reflects a solid year-to-date growth rate of 36.96% compared to the same period last year.
Market Context: The stock price closed at NT$23.9, with a slight decline of 0.42% over the past five trading days. This performance is relatively in line with the broader biotechnology index, which fell by 0.91% during the same period.
Institutional Activity: Institutional investors have shown a cautious stance, with a net sell-off of 153 shares by foreign investors over the last five days. Domestic institutional investors, including investment trusts and proprietary traders, have remained inactive in the stock.